Bronchial Ablation for Treatment of Asthma (BATA) Trial
- Conditions
- Asthma
- Interventions
- Device: SyMap Bronchial Ablation SystemDevice: Boston Scientific Alair System
- Registration Number
- NCT03765307
- Lead Sponsor
- SyMap Medical (Suzhou), Ltd.
- Brief Summary
To evaluate the safety and efficacy of a bronchial radiofrequency ablation system (SyMap Medical (Suzhou) Ltd) in a population of subjects with severe asthma who are still symptomatic despite being managed on high-dose Inhaled Corticosteroids (ICS) and Long-Acting β2-adrenergic Agonists (LABA).
- Detailed Description
This will be a prospective, multicenter, randomized, clinical study comparing the SyMap bronchial radiofrequency ablation system to the Boston Scientific Bronchial Thermoplasty System (Alair System). The study population consisted of subjects with severe asthma who are still symptomatic despite being managed on high dose ICS and LABA. Patients with severe asthma who still have symptoms, despite the standard drug maintenance recommended by the guidelines, after signing the informed consent, who meet the inclusion exclusion criteria enter the baseline period and continued to use uniform ICS and LABA, which will last at least 4 weeks. Patients with at least two days asthma symptoms during the baseline period, and meet the eligibility criteria are assigned to the experimental or control group at a 1:1 ratio based on a central randomized system. A total of 160 subjects will be enrolled, 80 in the experimental group and 80 in the control group. The experimental group is treated with SyMap radiofrequency ablation system, and the control group is treated with the same procedure using Boston Scientific Bronchial Thermoplasty Aliar System. For subjects in the experimental group and the control group, follow-up by telephone call will be performed at 1, 2, 7 days after each procedure and at 1, 2, 4, 5, 7, 8, 9, 10, 11, 15, 18, 21, 27, 30, 33, 39, 42, 45, 51, 54, and 57 months after the third procedure, and outpatient follow-up will be performed at 6 weeks, 3, 6，12，24, 36, 48 and 60 months after the third procedure. ICS and LABA are administered within five years after the third procedure. The difference in the rate of severe asthma exacerbations per year (the number of severe asthma exacerbations per person per year), at 12 months after bronchial radiofrequency ablation, is the primary endpoint of the study, and the success rate of procedure, postoperative adverse events, and serious adverse events are safety endpoints.
This study is conducted by an independent clinical monitoring organization, a data management and statistical center to collect and statistically analyze all relevant clinical and laboratory data.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 160
- Subject is an adult between the ages of 18 to 65 years;
- Diagnosed with asthma who required regular asthma maintenance medication in the past 6 months as follows:
ICS ≥1000 μg/day beclomethasone or equivalent and LABA ≥1000μg /day salmeterol or equivalent.
Other medications were allowed, including leukotriene modifiers, and Oral Corticosteroids (OCS) ≤ 10mg/day.
- At least two days of asthma symptoms during 4-weeks of the baseline period.
- Pre-bronchodilator Forced Expiratory Volume in one second (FEV1) of greater than or equal to 45% of predicted.
- Non-smoker (less than 10 pack per year) last for 1 year or greater.
- Baseline AQLQ Score less than or equal to 6.25
- Willingness and ability to comply with the outpatient follow-up.
- Pre-bronchodilator Forced Expiratory Volume in one second (FEV1) of less than 45% of predicted.
- 3 or more hospitalizations for exacerbations of asthma in the past 12 months;
- More than 3 lower respiratory tract infections requiring antibiotics in the past 12 months
- More than 4 of oral steroid use for exacerbations of asthma in the past 12 months
- Chronic sinusitis
- Uncontrolled gastroesophageal reflux disease, defined as a significant increase in treatment over the past 6 weeks
- Sensitivity to medications required to perform bronchoscopy (such as lidocaine and benzodiazepines)
- Use of an implantable electrical stimulation device, such as a pacemaker, a cardiac defibrillator or a deep nerve or deep brain stimulator;
- Severe emphysema caused by chronic obstructive pulmonary disease (COPD).
- Use of systemic immunosuppressants, beta adrenergic blockers, or anticoagulants.
- History of fatal asthma.
- Uncontrolled obstructive sleep apnea
- Intubation or admission to the ICU for asthma exacerbations within 2 years prior to treatment
- Hemorrhagic or malignant tumors or Coagulopathy.
- Lower bronchial stenosis or distal complete atelectasis or other severe bronchial and pulmonary lesions, as Thoracic spiral CT showed
- Poor compliance judged by the investigator, or other medical conditions that are not suitable for the study
- Related contraindications for bronchoscopy
- Pregnant, lactating women, or patients with a birth plan in the next year
- Previously undergone bronchial thermoplasty
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description SyMap Bronchial Ablation Group SyMap Bronchial Ablation System The experimental group is treated using SyMap Bronchial Radiofrequency Ablation system, including disposable bronchial radiofrequency ablation catheter (Model: BA125T) and Bronchial radiofrequency ablation instrument (Model: ELATION S3). Boston Scientific Bronchial Thermoplasty Group Boston Scientific Alair System The control group is treated using Boston Scientific Alair System, including Bronchial radiofrequency ablation catheter Alair (Model: ATS2-5 ) and Bronchial radiofrequency ablation instrument (Model: ATS200)
- Primary Outcome Measures
Name Time Method Rate of severe asthma exacerbations per year (the number of severe asthma exacerbations per person per year) 12 months Definition of severe asthma exacerbations:
1. Patients who do not receive oral corticosteroids maintenance, systemic corticosteroids (tablets, suspensions or injections) need to be used, or ICS doses doubled, due to increased asthma symptoms.
2. Patients who have been treated with oral corticosteroids maintenance daily or every other day, the daily dose of systemic corticosteroids needs to be increased, due to increased asthma symptoms;
Note: Severe asthma exacerbations of the above described two conditions, after treatment with corticosteroids, stabilized for 1 week or more, then recurring asthma symptoms will be counted as a single severe asthma exacerbations.
- Secondary Outcome Measures
Name Time Method Rate of severe asthma exacerbations per year 24, 36, 48 and 60 months the number of severe asthma exacerbations per person per year
Change in Integrated Asthma Quality of Life Questionnaire (Integrated AQLQ) Score from baseline 3, 6, 12, 24, 36, 48 and 60 months Asthma Quality of Life Questionnaire consists of 32 items covering asthma-related symptoms and limitations during the 2 weeks preceding administration of the questionnaire, the responses are scored on a scale of 1 to 7, with higher numbers indicating a better quality of life. Integrated AQLQ is the average of the 6-, 9-, and 12- month scores.The proportion of subjects within each group that achieved an AQLQ score change of 0.5 or greater is analyzed.
Numbers of severe asthma exacerbations 6 weeks, 12, 24, 36, 48 and 60 months Asthma Quality of Life Questionnaire Score (AQLQ) 6 weeks, 3, 6, 12, 24, 36, 48 and 60months Asthma Quality of Life Questionnaire consists of 32 items covering asthma-related symptoms and limitations during the 2 weeks preceding administration of the questionnaire, the responses are scored on a scale of 1 to 7, with higher numbers indicating a better quality of life.
Percent of Symptom-Free Days 12 months Forced Expiratory Volume in one second (FEV1) 6 weeks, 12, 24, 36, 48 and 60months Modified Asthma Control Questionnaire (ACQ-6) Score 6 weeks, 3, 6, 12, 24, 36, 48 and 60months Modified Asthma Control Questionnaire (ACQ-6) Consists of six questions (1 for bronchodilator use and 5 for asthma symptoms). The scores range from 0 (full control) to 6 (seriously uncontrolled). The ACQ-6 average score is the mean of the patient score. The average score ≤ 0.75 indicates that the asthma control is good, 0.75 \~ ≤ 1.5 prompts partial control, \> 1.5 prompts poor control. The proportion of subjects within each group that achieved an AQLQ score change of 0.5 or greater was analyzed.
Peak expiratory flow (PEF) 6 weeks, 12 , 24, 36, 48 and 60 months
Trial Locations
- Locations (15)
Shanghai Tenth People's Hospital
🇨🇳Shanghai, Shanghai, China
Chinese Pla General Hospital
🇨🇳Beijing, Beijing, China
University of Chinese Academy of Sciences Shenzhen Hospital
🇨🇳Shenzhen, Guangdong, China
Hebei Chest Hospital
🇨🇳Shijiazhuang, Hebei, China
The First Affiliated Hospital of Guangzhou Medical University
🇨🇳Guangzhou, Guangdong, China
The Third Affiliated Hospital Of Qiqihar Medical University
🇨🇳Qiqihar, Heilongjiang, China
The Second Hospital of Hebei Medical University
🇨🇳Shijiazhuang, Hebei, China
The First Affilated Hospital with Nanjing Medical University
🇨🇳Nanjing, Jiangsu, China
Suzhou Municipal Hospital
🇨🇳Suzhou, Jiangsu, China
Northern Jiangsu People's Hospital
🇨🇳Yangzhou, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
🇨🇳Xuzhou, Jiangsu, China
Northern Theater Command General Hospital
🇨🇳Shenyang, Liaoning, China
Yantai Yuhuangding Hospital
🇨🇳Yantai, Shandong, China
Tangdu Hospital, Second Affiliated Hospital of Air Force Medical University
🇨🇳Xi'an, Shanxi, China
The Second Affiliated Hospital Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China